

Fujisawa Canada donates two paediatric dermatology fellowships

MARKHAM, ONTARIO – February 28, 2005 – Fujisawa Canada announced today that it has donated funding to support two paediatric-dermatology fellowships as part of its on-going commitment to the Canadian dermatology community.

The Fujisawa - Bernice R. Krafchik Paediatric Dermatology Fellowship, initiated for the first time this year, will be used to train Dr. Perla Lansang, a dermatologist visiting The Hospital for Sick Children (Sick Kids) in Toronto from the Philippines. Her year spent in Toronto will allow her to see paediatric dermatology patients on her return to her home country. "This discipline is a highly sub-specialized area that encompasses a wide variety of diseases. We need experts trained in this area to act as a resource to primary care physicians and other specialists who see children with skin problems," explains Dr. Miriam Weinstein, paediatric dermatologist at Sick Kids. "The fellowship was named after Dr. Bernice Krafchik who was the Director of the Section of Dermatology, Division of Paediatric Medicine at The Hospital for Sick Children from 1995 to 2003. She is a renowned contributor to the field of paediatric dermatology through her numerous lectures locally, nationally and internationally and has authored over 100 publications."

The second Fujisawa Paediatric Dermatology Fellowship, donated for a second consecutive year to CHU Sainte-Justine of Montreal, is also used to train a dermatologist in paediatric dermatology with a special focus on clinical research. "Training dermatologists in this field fills a need and also contributes to the development and promotion of our subspecialty locally, nationally and internationally. Our fellow, Dr. Fatemeh Jafarian, reviewed our group's experience with malignant melanoma in childhood and adolescence, presented papers at several national and international meetings, and is currently setting up a Dermatology Follow-up Clinic for our institution's organ-graft recipients, a first in paediatrics to our knowledge. She also has several other clinical research projects underway, such as a review of opportunistic fungal infections in an immuno-suppressed population," explains Dr. Julie Powell, director of the Paediatric Dermatology Division at CHU Sainte-Justine.

"An increasing number of dermatologists are retiring or are about to do so," stated Robert Goldberg, Product Manager at Fujisawa Canada, Inc. "We, at Fujisawa Canada, strongly hope that these fellowships will not only help to further dermatological research in Canada, but to also support new recruits to this very important specialty."

Fujisawa Canada, Inc.

Fujisawa Canada, Inc., a research-based company, has its Canadian headquarters in Markham, Ontario and is a wholly owned subsidiary of Fujisawa Healthcare, Inc. Fujisawa Healthcare, Inc. is a wholly owned subsidiary of Fujisawa Pharmaceutical Co. Ltd., based in Osaka, Japan. Fujisawa Pharmaceutical Co. Ltd., founded in 1894, develops, manufactures and markets proprietary pharmaceutical products in Canada and the rest of the world. Their product line includes tacrolimus (Protopic[®]), a non-steroid topical therapy for atopic dermatitis (eczema). Additional information on Fujisawa Canada, Inc. and its products can be found on the company's Website at www.fujisawa.com. On April 1, 2005 Fujisawa Pharmaceutical Co. Ltd. and Yamanouchi Pharmaceutical Company will merge to form Astellas Pharma, Inc.

For more information and to book interviews contact:

Communications MECA

416-425-9143 or 1-866-337-3362